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Epidemiological evidence shows that people with thicker, or higher stage, melanomas have
lower vitamin D status compared to those with thinner tumours. Evidence from experimental
studies is inconsistent, but some suggest that administration of vitamin D metabolites can
decrease tumour aggressiveness.
Objectives
Determine the relationship between vitamin D status at diagnosis and melanoma thickness
(as an indicator of prognosis), in a subtropical setting with high melanoma incidence.
Methods
We recruited 100 melanoma patients in Brisbane, Australia within days of their diagnosis.
Data on factors previously associated with melanoma risk or prognosis were collected by
questionnaire and physical examination. Serum for 25-hydroxyvitamin D3 [25(OH)D] levels
was collected prior to wider excision biopsy; histological indicators of prognosis were ob-
tained from pathology reports. We used multivariable logistic regression models to analyse
the association between Breslow thickness (0.75 mm compared to <0.75 mm), Clark level
(2–5 compared to 1) and presence of mitoses, and vitamin D status.
Results
Serum 25(OH)D <50 nmol/L (versus50 nmol/L) was associated with a nearly four-fold
increase in risk of having a thicker tumour (Adjusted OR = 3.82, 95% CI: 1.03, 14.14;
p = 0.04, adjusted for age, sex, skin phototype, body mass index and season at diagnosis).
There was no significant association with Clark level or presence of mitosis. Serum 25(OH)
D levels in the highest quartile (69.8 nmol/L) were not associated with a more favourable
prognosis.
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Conclusions
Vitamin D deficiency at the time of melanoma diagnosis is associated with thicker tumours
that are likely to have a poorer prognosis. Ensuring vitamin D levels of 50 nmol/L or higher
in this population could potentially result in 18% of melanomas having Breslow thickness of
<0.75 mm rather than0.75 mm.
Introduction
Cutaneous melanoma is common in developed countries: it was the 10th most common cancer
in the very highly developed regions of the world in 2012 and 230,000 new cases were reported
worldwide [1]. Incidence rates continue to increase in most countries with predominantly fair-
skinned populations, particularly in older people [2]. Mortality rates are also increasing in
many of these countries, and there were over 55,000 deaths from melanoma in 2012 [1].
Survival from melanoma is best predicted by Breslow thickness (the microscopic measure-
ment of the distance between the upper layer of the epidermis and the deepest point of tumour
spread) and the presence of ulceration [3, 4], as well as mitotic rate [5, 6]. Level of invasion
(Clark level) is a significant predictor in patients with thin melanomas (1 mm or less) [4]. Sur-
vival rates also depend on the melanoma stage, with 10-year survival varying from 93% for the
thinnest tumours with no evidence of spread (Stage 1A) to 39% for thick tumours with evi-
dence of metastasis (Stage IVb) [7].
Exposure to solar ultraviolet radiation (UVR) is the major risk factor for melanoma in fair-
skinned populations [3, 8–10]. However, previous research has suggested that higher (com-
pared to lower) self- reported lifetime intermittent sun exposure is associated with a lower risk
of death within five years of diagnosis (HR = 0.6, 95% CI = 0.3, 1.0, p = 0.04) [11]. One hypoth-
esis is that these apparent beneficial effects of sun exposure on survival might be mediated
through improvement in vitamin D status [12].
Experimental studies provide mixed support for this hypothesis. Cultured melanoma cells
express the 25-hydroxylase enzyme that converts the circulating form of vitamin D,
25-hydroxyvitamin D3 (25(OH)D), to the biologically active form, 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] [13], but recent evidence suggests that most melanoma cell lines are resistant to
the anti-proliferative effects of 1,25(OH)2D3 [14]. In immunosuppressed mice, administration
of pharmacological doses of 1,25(OH)2D3 suppressed melanoma growth and inhibited metas-
tases for one human solid xenograft melanoma line, but not another [15]. Nevertheless, studies
in other cancers demonstrate regulatory effects of 1,25(OH)2D3 on cellular growth and angio-
genesis that would plausibly improve cancer prognosis.
There is more consistency in the findings from the small number of epidemiological studies
examining this question. Serum 25(OH)D levels (at variable times post-diagnosis) were signifi-
cantly lower in patients with Stage IV compared to with Stage 1 melanoma (median 33 nmol/L
compared to 41 nmol/L, p = 0.006 [16]; 21 nmol/L compared to 36 nmol/L, p = 0.04 [17]) in
two studies. In another study there was a significant trend toward lower 25(OH)D levels (taken
3–6 months after diagnosis) in association with higher Breslow thickness (adjusted mean 25
(OH)D:<0.75 mm = 56 nmol/L;>3 mm = 49 nmol/L) [18]. A major issue with each of these
studies is that blood sampling occurred at various times after the diagnosis of melanoma and
could reflect the increased sun awareness and protection that occurs after skin cancer
diagnosis.
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Australia has the highest incidence rate of cutaneous melanoma in the world [1, 19] due to
high levels of UVR and an outdoors lifestyle. Yet even in this sunny environment 23% of the
population had serum 25(OH)D levels of<50 nmol/L (commonly considered to be sub-
optimal) in the most recent Australian Health Survey [20]. A causal link between vitamin D
deficiency at diagnosis, and poorer prognosis after diagnosis, is of considerable public health
importance, amenable to intervention, particularly where melanoma incidence is high.
We examined serum 25(OH)D levels and sun exposure history at melanoma diagnosis in
relation to histopathological indicators of prognosis: Breslow thickness [21], ulceration [3],
Clark level [22], and presence of mitotic activity [5, 6] in patients with newly diagnosed mela-
noma in Brisbane, Australia.
Materials and Methods
Study population and setting
Participants were patients aged 18 years and older with histologically confirmed cutaneous
melanoma, recruited prior to wider-excision surgery from two plastic surgery practices in Bris-
bane, Australia. Brisbane is geographically situated at Latitude 27.5° South, Longitude 153°
East. Recruitment took place between 1 July 2010 and 27 July 2011. Exclusion criteria included:
diagnosis made from metastatic or lymph node tissue; self-reported pre-existing conditions
that could interfere with the vitamin D pathway such as chronic liver or kidney disease; trans-
plant recipients; or receiving high dose calcium therapy.
The Human Research Ethics Committee of the Queensland University of Technology
(QUT) approved the conduct of the QUTMelanoma Study, and written informed consent was
obtained from all participants (QUT HREC Approval number: 0900000681).
Study procedures
In this region where the incidence of melanoma is high, when a melanoma is diagnosed by bi-
opsy or shave excision patients are usually “fast-tracked” to consult a surgeon within days of di-
agnosis, with wider-excision surgery scheduled as soon after that as is possible.
Participants were recruited prior to wider-excision surgery and provided with a question-
naire to be completed and returned at the post-operative visit. Questionnaire data included de-
mographics (age, sex, birthplace, highest level of education completed, occupational history),
skin phenotypic characteristics as a teenager (natural hair colour and mole and freckle density
were ascertained by matching answers with pictures depicting different categories), burning
and tanning propensity, past history of sun exposure over the life course (obtained by asking
place of residence and time spent in the sun on work days and non-work days), historical use
of sun protection (sunscreen, hats, sunglasses, long sleeves, shade), history of sunburns result-
ing in either blistering, prolonged soreness or peeling of the skin, and history of previous
melanoma.
At the post-operative appointment a registered nurse trained in skin examination (CW) un-
dertook a count of naevi that were 2 mm or greater in diameter on the head, neck, arms and
trunk (from the hipline up), and the freckle and solar lentigo density (none, few/some, heavy)
in three regions: the forearms, the face and the shoulders. Natural skin pigmentation (left
upper, inner arm) was measured using reflectance spectrophotometry (Minolta CM2500d
spectrophotometer, Minolta Camera Company, Ltd., Osaka, Japan). Data were also collected
on use of vitamin supplements, height and weight.
Data relating to melanoma type, anatomic site, presence of solar elastosis and the histopath-
ological prognostic indicators [3, 5, 6] of Breslow thickness, ulceration, Clark level and
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presence of mitotic activity, were obtained from the histopathology reports of both the biopsy
and wider-excision samples.
A blood sample was collected prior to wider excision surgery; serum was aliquoted and
stored at -80°Celsius until the completion of the study. The 25(OH)D concentration was mea-
sured in two batches using a commercial chemiluminescent immunoassay (LIAISON 25_OH
Vitamin D TOTAL assay: DiaSorin, Inc., Stillwater, MN), with intra-assay variability of 3–6%
and inter-assay variability of 6–9%. The laboratory is certified by the Vitamin D External Qual-
ity Assessment Scheme (DEQAS).
Statistical analysis
Data were described using means and standard deviations, medians and interquartile ranges or
numbers and proportions, depending on the data type and the distribution. Relationships be-
tween variables were tested in univariate analyses using Chi-squared or Fisher’s exact tests for
categorical variables, and Kruskal-Wallis, Anova or Students t-test for comparisons of continu-
ous variables across categories of independent variables.
Serum 25(OH)D level was treated as a continuous variable and also dichotomised to exam-
ine the effect of low vitamin D status using both the lowest quartile (less than 45.3 nmol/L) and
a commonly used cut-point: less than 50 nmol/L. The latter is commonly considered to be sub-
optimal [23, 24]. We also investigated whether higher vitamin D status (highest quartile:69.8
nmol/L) was associated with histological indicators of melanoma prognosis.
Natural skin phototype was derived from the L and b spectrophotometric measure-
ments using the formula: [arctangent((L-50)/ b)]180/3.14159 to calculate the ITA (Indi-
vidual Topography Angle) value [25]. ITA was treated as both a continuous variable (ITA
value) and as an ordinal categorical variable representing the three ITA skin types seen in
the study: intermediate/medium (>28° to 41°), light/fair (>41° to 55°) and very light/
very fair (>55° to 90°).
BMI (Body Mass Index) was calculated by dividing weight in kilograms by height in meters
squared (kg/m2). Supplement usage was classified as takes no supplements, takes a multivita-
min, and takes vitamin D supplements. Naevus burden was grouped into 0–9 naevi, 10–39
naevi, and40 naevi to reflect low, medium and high burden.
The prognostic outcome indicator of Breslow thickness was dichotomised (0.75 mm ver-
sus<0.75 mm) according to past evidence that this is a rational cut-point [21]. More recently
the AJCC [7] has described a cut-point of 1.00 mm, but due to the small number of study mela-
nomas greater than 1.00 mm (n = 12) in this study, the 0.75 mm cut-point was preferable. The
other outcome indicators were also dichotomised: Clark level (levels 2–5 versus level 1), ulcera-
tion (present versus absent) and mitotic activity (present versus absent). Ultimately, ulceration
was not included in multivariable analyses due to low numbers (n = 4). If participants had been
diagnosed with more than one melanoma simultaneously, only the first melanoma reported in
the histopathology for the biopsy specimen was included in the analysis. Any melanomas not
reported as lentigo maligna, superficial spreading or nodular melanoma, were grouped together
as “other melanoma”.
We used logistic regression to examine the relationship between vitamin D status (as
both continuous and categorical variables as noted above) and each of the dichotomous out-
comes. Potential confounders identified from the univariate analyses were entered into a
multivariable logistic regression model and were retained in the model if their inclusion
changed the coefficient of the main exposure of interest [25(OH)D] by 5% or greater. Age
(in years) and sex were retained in all multivariable models. A p value of less than 0.05 (two-
sided test) was considered statistically significant. Tests for linear trend were conducted by
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fitting ordered categories of a variable as a single ordinal variable in the regression models;
trend p values were based on the Wald test. Participants with missing data were excluded
from analyses using those variables. All analyses were carried out in Stata IC version 11.2
(Stata Corporation, 2009. College Station, TX).
Results
Of the 102 patients who satisfied the inclusion and exclusion criteria, 100 participated in the
study (98% participation rate). Histopathology reports were obtained for all participants, 99%
of participants completed the questionnaire, 98% took part in the skin examination, and blood
samples for 25(OH)D analysis were obtained from all participants prior to wider excision sur-
gery. The youngest participant was 26 years old, and the oldest 89 years. The mean age was
61 years (SD = 13). Average body mass index (BMI) was 27 kg/m2 (SD = 5); 40% of participants
reported ever smoking and 6% currently smoked. Vitamin D supplement use was reported by
9% of participants and 2% reported taking a multivitamin. A previous melanoma was reported
by 13% of participants. In this group, 77% were 60 years or older and equally distributed by
sex. The deepest reported Breslow thickness was 7.8 mm.
The mean serum 25(OH)D concentration was 58 nmol/L (SD = 19), with a range from
16–114 nmol/L. Over one-third of participants (36%) had serum 25(OH)D level of<50 nmol/
L. Variation in serum 25(OH)D levels and vitamin D status according to baseline characteris-
tics are shown in Table 1. Sub-optimal 25(OH)D levels were more common in those with
higher body mass index (BMI) and fairer skin type, although these trends were not statistically
significant. However, when Individual Topography Angle (ITA) skin type was treated as a con-
tinuous variable it was significantly associated with 25(OH)D concentration (beta coefficient =
-0.66, 95% CI = -1.22, -0.11, p = 0.02). As expected, 25(OH)D levels<50 nmol/L were most fre-
quent in winter and least in summer, while 25(OH)D levels in the highest quartile were most
common in samples taken in autumn. A higher proportion of the group who reported a previ-
ous melanoma had serum 25(OH)D levels<50 nmol/L, but this was not statistically
significant.
Analyses of baseline characteristics of patients in relation to the prognostic indicators are
reported in Table 2 and show that those with fairer skin type were more likely to present with
thicker melanomas and for mitoses to be present. There was no association with smoking
categorized as ever vs. never or as a continuous variable of total number of pack years (data not
shown). There was a positive association between BMI and Breslow thickness (OR = 1.12, 95%
CI = 1.01, 1.26, p = 0.04 per unit increase in BMI). Higher Breslow thickness was more com-
monly found in those reporting medium or high sun exposure, more than 20 childhood sun-
burns, and in those with presence of solar elastosis, but none of these associations was
statistically significant (see Table 2). Similarly there was no association between serum 25(OH)
D concentration and the anatomic location or the histological features of the melanoma in
crude analyses (see Table 3).
In separate multivariate logistic regression models with adjustment for confounding factors
(see Table 4), higher 25(OH)D levels (per 10 nmol/L) were associated with decreased odds of
having an indicator of poorer prognosis, but this was not statistically significant for any
outcome.
However, lower vitamin D status, either in absolute (<50 nmol/L) or relative (lowest
quartile compared to the other three quartiles) terms, was associated with increased odds of
having higher Breslow thickness (see Table 5). Indeed, there was a nearly four-fold increase
in the odds of higher Breslow thickness in association with 25(OH)D <50 nmol/L and there
was a greater than five-fold increase for the lowest quartile compared with the highest,
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where the cut-off point was a little lower (45.3 nmol/L). There was no association between
vitamin D status and either Clark level (see Table 6) or presence of mitotic activity (see
Table 7). In addition, a 25(OH)D level in the highest quartile (compared to the other three
quartiles) was not associated with a reduced risk of having an indicator of poorer prognosis.
Inclusion of past history of melanoma or use of vitamin D supplementation did not alter the
effect estimates reported here.
Discussion
Here we found that vitamin D deficiency at the time of melanoma diagnosis was associated
with higher Breslow thickness, a known marker of poorer prognosis. There was no significant
association between vitamin D and two other histopathological indicators of prognosis. Fur-
thermore, we found no significant association between markers of prognosis and past or recent
sun exposure, history of childhood sunburns or solar elastosis.
Many studies have investigated risk factors for melanoma, but less is known about the fac-
tors that influence melanoma prognosis. A previous study showed an inverse association




25(OH)D level (nmol/L) mean
(SD)
25(OH)D <50 nmol/L n
(%)
Upper quartile 25(OH)D (69.8 nmol/L)
n (%)
Age
<60 years 40 (40) 50.1 (17.8) 14 (35) 8 (20)
60 years 60 (60) 59.6 (20.1) 22 (37) 17 (28)
p-value 0.37 0.87 0.35
BMI
<25.0 34 (35) 60.0 (18.4) 10 (29) 9 (27)
25–29.9 36 (37) 59.3 (22.1) 13 (36) 11 (31)
30+ 27 (28) 53.4 (16.3) 13 (48) 4 (15)
p for trend 0.36 0.32 0.34
ITA skin type
Intermediate/medium 8 (8) 67.5 (31.8) 2 (25) 3 (38)
Light/fair 70 (72) 58.0 (17.6) 25 (36) 17 (24)
Very light/very fair 20 (20) 53.4 (18.1) 9 (45) 4 (20)
p for trend 0.22 0.58 0.62
Season at diagnosis
Winter 29 (29) 52.0 (17.3) 15 (52) 4 (14)
Spring 25 (25) 58.3 (22.5) 11 (44) 4 (16)
Summer 20 (20) 62.3 (19.4) 3 (15) 7 (35)
Autumn 26 (26) 61.8 (16.8) 7 (27) 10 (39)
p for trend 0.18 0.04 0.09
Sunscreen use 5 years
ago
Most of the time 7 (7) 60.0 (19.6) 3 (43) 2 (29)
Sometimes 31 (31) 61.0 (19.9) 11 (36) 8 (26)
Rarely/never 61 (62) 56.4 (19.1) 22 (36) 15 (25)
p for trend 0.54 0.95 1.00
Values not summing to 100 indicate missing data.
SD: standard deviation; BMI: body mass index; ITA: Individual topography angle.
doi:10.1371/journal.pone.0126394.t001
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Table 2. Baseline characteristics of participants in relation to Breslow thickness, Clark level andmitotic activity.
Characteristics Frequency n
(%)
Breslow thickness (0.75 mm) n
(%)
Clark level (Levels 2–5) n
(%)
Mitotic activity (present) n
(%)
Sex
Male 56 (56) 8 (14) 29 (52) 15 (27)
Female 44 (44) 9 (20) 26 (59) 8 (18)
p-value 0.42 0.47 0.31
Age
<60 years 40 (40) 9 (23) 23 (58) 10 (25)
60 years 60 (60) 8 (13) 32 (53) 13 (22)
p-value 0.23 0.68 0.70
BMI
<25.0 34 (35) 3 (9) 17 (50) 3 (9)
25–29.9 36 (37) 7 (19) 20 (56) 11 (31)
30+ 27 (28) 6 (22) 16 (59) 8 (30)
p for trend 0.33 0.79 0.05
ITA skin type
Intermediate/medium 8 (8) 0 (0) 3 (38) 0 (0)
Light/fair 70 (72) 9 (13) 37 (53) 13 (19)
Very light/very fair 20 (20) 7 (35) 14 (70) 9 (45)
p for trend 0.03 0.24 0.02
Reported UVR exposure
Low 18 (19) 2 (11) 9 (50) 4 (22)
Medium 38 (41) 8 (21) 21 (55) 6 (16)
High 37 (40) 5 (14) 20 (54) 10 (27)
p for trend 0.62 0.93 0.52
Naevi burden at diagnosis
0–9 25 (25) 3 (12) 15 (60) 5 (60)
10–39 45 (46) 8 (18) 21 (47) 12 (27)
40+ 28 (29) 5 (18) 18 (64) 5 (18)
p for trend 0.83 0.30 0.68
Solar elastosisa
Present 34 (71) 6 (18) 20 (59) 10 (29)
Absent 14 (29) 2 (14) 8 (57) 3 (21)
p-value 0.57 0.92 0.73
Childhood sunburns
0–5 40 (40) 6 (15) 21 (53) 7 (18)
6–20 44 (45) 7 (15) 27 (61) 12 (27)
> 20 15 (15) 3 (20) 6 (40) 3 (20)
p for trend 0.87 0.34 0.58
Skin checks in last 3
years
3 or more 46 (47) 5 (11) 20 (44) 10 (22)
1 or 2 28 (28) 6 (21) 16 (57) 7 (25)
Nil 25 (25) 5 (20) 18 (72) 5 (20)
p for trend 0.41 0.07 0.90
UVR: ultraviolet radiation.
aHistopathology reporting for solar elastosis available for n = 48 melanomas
doi:10.1371/journal.pone.0126394.t002
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between risk of death from melanoma and higher levels of sun exposure prior to diagnosis of
the melanoma (based on questionnaire data on intermittent sun exposure [high vs. low], severe
sunburn [yes/no] and presence of solar elastosis [yes/no]) [11]. In our smaller study, at a lower
latitude, no participant reported a history of no severe sunburns (compared to n = 173 [33% of
the study sample]) in Berwick et al), and 15% reported more than 20 severe sunburns. Further-
more, we report here on markers of melanoma prognosis, rather than death. Our findings did
not corroborate those of this previous study set in Connecticut, a much higher latitude location
(42°N), possibly because of the much higher sun exposure experience of our participants (and
Table 3. Summary descriptive statistics (frequency, mean, median, standard deviation and range) of serum 25(OH)D (nmol/L) and associations
with anatomic site and histological characteristics of the melanomas.
25-Hydroxyvitamin D concentration (nmol/L)
Characteristic (N) n (%) Mean SD Median Range P-value
Anatomic site (100) 0.87
Head & neck 27 (27) 56.8 16.6 58.6 21.1–99.6
Trunk 37 (37 59.1 17.1 58.9 37.9–114.0
Upper limbs 12 (12) 64.3 23.5 61.6 24.3–104.0
Lower limbs 24 (24) 55.1 22.9 54.9 15.8–101.0
Melanoma type (100) 0.55
LMa 29 (29) 59.9 17.7 59.8 21.1–99.6
SSMb 54 (54) 57.5 20.6 58.6 15.8–114.0
Nodular 2 (2) 73.3 43.5 73.3 42.5–104.0
Other melanomasc 15 (15) 55.2 14.3 52.7 32.8–85.7
Breslow thickness (100) 0.08
<0.75 mm 83 (83) 59.7 18.0 59.0 15.8–114.0
0.75 mm 17 (17) 50.7 23.4 42.5 24.3–104.0
Clark level (100) 0.22
Level 1 45 (45) 60.8 20.7 59.6 15.8–114.0
Level 2–5 55 (55) 56.0 17.9 53.3 24.3–104.0
Mitosis (100) 0.47
Absent 77 (77) 58.9 18.8 58.6 15.8–114.0
Present 23 (23) 55.6 20.9 57.8 24.5–104.0
a Lentigo maligna melanoma
b Superﬁcial spreading melanoma
c Includes lesions reported by histopathology report as “malignant melanoma” and other variations of malignant melanoma
doi:10.1371/journal.pone.0126394.t003
Table 4. Relationship of 25-hydroxyvitamin D concentration (per 10 nmol/L) to the histopathological indicators of melanoma prognosis with ad-
justment for confounding factors.
Model Crude OR 95% CI P-value Adjusted OR 95% CI P-value
Breslow thickness(0.75 mm) 0.75 0.54, 1.02 0.07 0.78a 0.55, 1.11 0.17
Clark level(Levels 2–5) 0.88 0.72, 1.09 0.26 0.93b 0.71, 1.22 0.60
Mitotic activity(present) 0.91 0.71, 1,17 0.47 0.96c 0.70, 1.33 0.82
OR: odds ratio; CI: conﬁdence interval.
a Adjusted for age, sex, ITA value, BMI, season at diagnosis
b Adjusted for age, sex, ITA value, BMI, season at diagnosis, naevi burden at diagnosis, number of primary school sunburns
c Adjusted for age, sex, ITA value, BMI, season at diagnosis, naevi burden at diagnosis, number of primary school sunburns
doi:10.1371/journal.pone.0126394.t004
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the lack of a truly “low” sun exposure group). Indeed, it is important to note the difference in
absolute received UVR dose of “high” and “low” sun exposure in studies from lower, compared
to higher, latitudes [26].
A few recent studies have suggested that there may be independent beneficial effects of sun
exposure and 25(OH)D levels for some disease outcomes [27, 28]. For melanoma, one plausible
pathway for a beneficial effect of sun exposure itself on melanoma prognosis is through alter-
ation of the skin microenvironment [29, 30]. Plausible pathways for a beneficial effect of higher
25(OH)D levels on cancer prognosis are well-described [31, 32]. We are unable to separate
these effects on prognosis in this cross-sectional study. Serum 25(OH)D level may be the im-
portant factor, or could be a marker of higher recent (and possibly usual) sun exposure, with
the latter the true protective factor for melanoma thickness at diagnosis. Nevertheless, here we
found no significant association between the prognostic indicators and measures of past
sun exposure.
Our results are consistent with previous studies from the Northern Hemisphere [16–18]
that have investigated associations between vitamin D status and melanoma prognosis. Fur-
thermore, the results reported here strengthen the causal attribution of previous findings by
ruling out an explanation of reverse causality due to lowered sun exposure (and 25(OH)D
levels) as a result of the diagnosis of melanoma. Similar associations between serum 25(OH)
D level and prognosis have been shown for other cancers such as gastric, breast and prostate
[33–35].
A causal role for vitamin D in melanoma prognosis is also supported by recent findings of
disturbance of the expression of vitamin D-related genes within melanomas. Both locally and
systemically, levels of the active form of vitamin D [1,25(OH)2D3] are dependent on the action
Table 5. Vitamin D status (lower quartile [<45.3 nmol/L], <50 nmol/L, upper quartile [69.8 nmol/L]) at time of diagnosis, in relation to Breslow
thickness (0.75 mm vs. <0.75 mm).
Vitamin D status Crude OR 95% CI P-value Adjusted ORa 95% CI P-value
45.3 nmol/L Reference Reference
<45.3 nmol/L 5.30 1.72, 16.40 0.01 5.03 1.32, 19.09 0.02
50 nmol/L Reference Reference
<50 nmol/L 3.59 1.18, 10.93 0.03 3.82 1.03, 14.14 0.04
69.8 nmol/L Reference Reference
<69.8 nmol/L 0.97 0.28, 3.34 0.96 0.83 0.19, 3.58 0.80
a Adjusted for age, sex, ITA value, BMI, season at diagnosis
doi:10.1371/journal.pone.0126394.t005
Table 6. Vitamin D status (lower quartile [<45.3 nmol/L], <50 nmol/L, upper quartile [69.8 nmol/L]) at time of diagnosis, in relation to Clark level
(Levels 2–5 vs. Level 1).
Vitamin D status Crude OR 95% CI P-value Adjusted ORa 95% CI P-value
45.3 nmol/L Reference Reference
<45.3 nmol/L 1.64 0.64, 4.18 0.30 1.28 0.38, 4.33 0.69
50 nmol/L Reference Reference
<50 nmol/L 1.77 0.76, 4.11 0.19 1.83 0.62, 5.44 0.27
69.8 nmol/L Reference Reference
<69.8 nmol/L 2.05 0.81, 5.23 0.13 1.56 0.48, 5.12 0.46
a Adjusted for age, sex, season at diagnosis, ITA value, supplements, BMI, naevi burden at diagnosis, primary school sunburns
doi:10.1371/journal.pone.0126394.t006
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of 1α-hydroxylase enzyme (encoded by CYP27B1) that converts 25(OH)D to 1,25(OH)2D3
and the catabolic 24-hydroxylase enzyme (encoded by CYP24A1) that converts 1,25(OH)2D3
to the much less biologically active 24,25-dihydroxvitamin D3 [24,25-(OH)2D3]. The effects of
1,25(OH)2D3 on gene transcription are mediated through binding with a nuclear vitamin D re-
ceptor (VDR). Reduced expression of CYP27B1 in primary melanomas was associated with
shorter overall survival [36] in one study, while expression of CYP24A1 was higher in naevi
and early stage melanomas compared to normal skin, but decreased with melanoma progres-
sion in another [37]. In particular, a lack of CYP24A1 expression was associated with poorer
prognosis. The findings suggest that elevated CYP24A1 expression may be important for the
formation of melanocytic naevi and early melanomagenesis. Expression of the VDR has been
shown to be reduced in highly pigmented melanomas and in the surrounding skin, and these
tumours have a poorer prognosis [38]. Similarly, the expression of VDR is significantly higher
in melanomas of less advanced, compared to more advanced, stages [39]. These genetic find-
ings lend weight to the importance of local levels of 1,25(OH)2D3, which are, in turn, depen-
dent on levels of the substrate, local or circulating 25(OH)D.
We observed a much lower prevalence of vitamin D serum 25(OH)D levels<50 nmol/L
(36%) in patients with melanoma than the 78% [16] and 74% [17] reported by others, probably
because of the more tropical study setting. The previous studies were undertaken at latitudes
above 49°North [16, 18], whereas our study was conducted at 27°South, and over a twelve
month period. Nevertheless, the observed prevalence of levels<50 nmol/L was higher than
that recently reported for Queensland in the Australian Health Survey (11%) [20]. Lower 25
(OH)D levels in people with melanoma compared to healthy controls have been previously re-
ported [17], although here the different vitamin D assays used in the two studies may also have
contributed to the differences observed.
A major strength of this study is the collection of blood samples within days of diagnosis,
before potential changes in sun-exposure patterns occurred. The “real-time” serum collection
also allowed us to adjust for season in all multivariable analyses. This is particularly important,
as 25(OH)D levels vary according to the season of the blood draw [40, 41]. The measurement
of total 25(OH)D concentrations in one laboratory ensured standardization of the assay tech-
nique. Further, we were able to comprehensively adjust for potential confounders. The high re-
cruitment rate (98%) and the sample size (N = 100) which represents approximately 9% of the
melanomas diagnosed annually in the Brisbane area [42], make it more likely that our sample
was representative of the population eligible to take part in this study. The sample is also repre-
sentative with respect to the subtypes and anatomic sites of melanoma seen in Queensland. For
example, the most common melanoma subtype seen in this study, superficial spreading
Table 7. Vitamin D status (lower quartile [<45.3 nmol/L], <50 nmol/L, upper quartile [69.8 nmol/L]) at time of diagnosis, in relation to mitotic activi-
ty (present vs. absent).
Vitamin D status Crude OR 95% CI P-value Adjusted ORa 95% CI P-value
45.3 nmol/L Reference Reference
<45.3 nmol/L 2.47 0.89, 6.80 0.08 2.21 0.56, 8.68 0.26
50 nmol/L Reference Reference
<50 nmol/L 1.60 0.61, 4.21 0.34 2.12 0.72, 6.19 0.17
69.8 nmol/L Reference Reference
<69.8 nmol/L 0.40 0.27, 2.39 0.70 0.40 0.10, 1.69 0.21
a Adjusted for age, sex, season at diagnosis, ITA value, BMI, reported adult sun exposure, adult sunburns, naevi burden at diagnosis, primary
school sunburns
doi:10.1371/journal.pone.0126394.t007
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melanoma (54%), was also the most commonly reported invasive melanoma subtype to the
Queensland Cancer Registry in the period 1982–2008 (55%) [43]. In the same period, the
trunk (34%) was the most common site of melanomas diagnosed in Queensland [43]. In our
study 37% of melanomas were located on the trunk.
In addition to these strengths, there were some limitations to our study. Firstly, this was a
cross-sectional study specifically examining vitamin D status in relation to Breslow thickness,
at the time of diagnosis of melanoma. Although Breslow thickness is considered to be a good
marker of prognosis, we do not have data on the outcomes for these patients with melanoma
and information on the pTNM characteristics, stage and melanization of the tumours was not
available. Further, we cannot infer that the associations shown are cause and effect, although
the genetic studies lend weight to an important role of local 1,25(OH)2D3 levels. However, we
cannot infer that vitamin D supplementation pre-diagnosis will be associated with lower Bre-
slow thickness at diagnosis, or that post-diagnosis vitamin D supplementation will affect prog-
nosis. Randomized controlled trials of vitamin D supplementation are required to address
these questions.
There is, however, value in examining the potential public health implications of our find-
ings. Only 9% of our participants were taking a vitamin D supplement. This means that the 25
(OH)D levels of the participants largely reflect their recent sun exposure (since dietary intake is
very low in the Australian population) [44]. If there was a causal association of a similar magni-
tude to that shown here, then ensuring that all members of the population achieved vitamin D
levels of 50 nmol/L or greater through the same mechanism as used by these participants,
would potentially result in approximately 18% of diagnosed melanomas having a Breslow
thickness of<0.75 mm, rather than0.75 mm, with potential survival gains.
This study provides support for an association between vitamin D deficiency (<50 nmol/L)
at the time of diagnosis and thicker melanoma at presentation (Breslow thickness0.75 mm).
The study was specifically examining the relationship between vitamin D status and several his-
topathological makers of melanoma prognosis, and not the risk of developing a melanoma. We
found no evidence to support that higher levels of past sun exposure, in this low latitude, high
ambient UVR setting, were associated with markers of more favorable prognosis. Brief (casual)
periods of sun exposure to a large surface area (avoiding sunburn) are most efficient for vita-
min D production. Maintaining a vitamin D level of50 nmol/L is advisable as our results in-
dicate that vitamin D deficiency is associated with thicker melanomas, which have, separately,
been shown to have poorer prognosis. The benefits of sun exposure to achieve vitamin D “suffi-
ciency” must be weighed against the risks of skin cancer development [44].
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